Cargando…

Clinical Characteristics and Outcome of Patients With Hemorrhagic Transformation After Intravenous Thrombolysis in the WAKE-UP Trial

Background: Hemorrhagic transformation (HT) is an important complication of intravenous thrombolysis with alteplase. HT can show a wide range from petechiae to parenchymal hematoma with mass effect with varying clinical impact. We studied clinical and imaging characteristics of patients with HT and...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Märit, Schlemm, Eckhard, Cheng, Bastian, Lettow, Iris, Quandt, Fanny, Boutitie, Florent, Ebinger, Martin, Endres, Matthias, Fiebach, Jochen B., Fiehler, Jens, Galinovic, Ivana, Thijs, Vincent, Lemmens, Robin, Muir, Keith W., Nighoghossian, Norbert, Pedraza, Salvador, Simonsen, Claus Z., Gerloff, Christian, Thomalla, Götz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7483750/
https://www.ncbi.nlm.nih.gov/pubmed/32982951
http://dx.doi.org/10.3389/fneur.2020.00957
_version_ 1783580958963793920
author Jensen, Märit
Schlemm, Eckhard
Cheng, Bastian
Lettow, Iris
Quandt, Fanny
Boutitie, Florent
Ebinger, Martin
Endres, Matthias
Fiebach, Jochen B.
Fiehler, Jens
Galinovic, Ivana
Thijs, Vincent
Lemmens, Robin
Muir, Keith W.
Nighoghossian, Norbert
Pedraza, Salvador
Simonsen, Claus Z.
Gerloff, Christian
Thomalla, Götz
author_facet Jensen, Märit
Schlemm, Eckhard
Cheng, Bastian
Lettow, Iris
Quandt, Fanny
Boutitie, Florent
Ebinger, Martin
Endres, Matthias
Fiebach, Jochen B.
Fiehler, Jens
Galinovic, Ivana
Thijs, Vincent
Lemmens, Robin
Muir, Keith W.
Nighoghossian, Norbert
Pedraza, Salvador
Simonsen, Claus Z.
Gerloff, Christian
Thomalla, Götz
author_sort Jensen, Märit
collection PubMed
description Background: Hemorrhagic transformation (HT) is an important complication of intravenous thrombolysis with alteplase. HT can show a wide range from petechiae to parenchymal hematoma with mass effect with varying clinical impact. We studied clinical and imaging characteristics of patients with HT and evaluated whether different types of HT are associated with functional outcome. Methods: We performed a post-hoc analysis of WAKE-UP, a multicenter, randomized, placebo-controlled trial of MRI-guided intravenous alteplase in unknown onset stroke. HT was assessed on follow-up MRI or CT and diagnosed as hemorrhagic infarction type 1 and type 2 (HI1 and HI2, combined as HI), and parenchymal hemorrhage type 1 and type 2 (PH1 and PH2, combined as PH). Severity of stroke symptoms was assessed using the National Institutes of Health Stroke Scale (NIHSS) at baseline. Stroke lesion volume was measured on baseline diffusion weighted imaging (DWI). Primary endpoint was a favorable outcome defined as a modified Rankin Scale score 0–1 at 90 days. Results: Of 483 patients included in the analysis, 95 (19.7%) showed HI and 21 (4.4%) had PH. Multiple logistic regression analysis identified treatment with alteplase (OR, 2.08 [95% CI, 1.28–3.40]), baseline NIHSS score (OR, 1.11 [95% CI, 1.05–1.17]), DWI lesion volume (OR, 1.03 [95% CI, 1.01–1.05]), baseline glucose levels (OR, 1.01 [95% CI, 1.00–1.01]) and atrial fibrillation (OR, 3.02 [95% CI, 1.57–5.80]) as predictors of any HT. The same parameters predicted HI. Predictors of PH were baseline NIHSS score (OR, 1.11 [95% CI, 1.01–1.22]) and as a trend treatment with alteplase (OR, 2.40 [95% CI, 0.93–6.96]). PH was associated with lower odds of favorable outcome (OR 0.25, 95% [CI 0.05–0.86]), while HI was not. Conclusion: Our results indicate that HI is associated with stroke severity, cardiovascular risk factors and thrombolysis. PH is a rare complication, more frequent in severe stroke and with thrombolysis. In contrast to HI, PH is associated with worse functional outcome. The impact of HT after MRI-guided intravenous alteplase for unknown onset stroke on clinical outcome is similar as in the trials of stroke thrombolysis within a known early time-window.
format Online
Article
Text
id pubmed-7483750
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-74837502020-09-25 Clinical Characteristics and Outcome of Patients With Hemorrhagic Transformation After Intravenous Thrombolysis in the WAKE-UP Trial Jensen, Märit Schlemm, Eckhard Cheng, Bastian Lettow, Iris Quandt, Fanny Boutitie, Florent Ebinger, Martin Endres, Matthias Fiebach, Jochen B. Fiehler, Jens Galinovic, Ivana Thijs, Vincent Lemmens, Robin Muir, Keith W. Nighoghossian, Norbert Pedraza, Salvador Simonsen, Claus Z. Gerloff, Christian Thomalla, Götz Front Neurol Neurology Background: Hemorrhagic transformation (HT) is an important complication of intravenous thrombolysis with alteplase. HT can show a wide range from petechiae to parenchymal hematoma with mass effect with varying clinical impact. We studied clinical and imaging characteristics of patients with HT and evaluated whether different types of HT are associated with functional outcome. Methods: We performed a post-hoc analysis of WAKE-UP, a multicenter, randomized, placebo-controlled trial of MRI-guided intravenous alteplase in unknown onset stroke. HT was assessed on follow-up MRI or CT and diagnosed as hemorrhagic infarction type 1 and type 2 (HI1 and HI2, combined as HI), and parenchymal hemorrhage type 1 and type 2 (PH1 and PH2, combined as PH). Severity of stroke symptoms was assessed using the National Institutes of Health Stroke Scale (NIHSS) at baseline. Stroke lesion volume was measured on baseline diffusion weighted imaging (DWI). Primary endpoint was a favorable outcome defined as a modified Rankin Scale score 0–1 at 90 days. Results: Of 483 patients included in the analysis, 95 (19.7%) showed HI and 21 (4.4%) had PH. Multiple logistic regression analysis identified treatment with alteplase (OR, 2.08 [95% CI, 1.28–3.40]), baseline NIHSS score (OR, 1.11 [95% CI, 1.05–1.17]), DWI lesion volume (OR, 1.03 [95% CI, 1.01–1.05]), baseline glucose levels (OR, 1.01 [95% CI, 1.00–1.01]) and atrial fibrillation (OR, 3.02 [95% CI, 1.57–5.80]) as predictors of any HT. The same parameters predicted HI. Predictors of PH were baseline NIHSS score (OR, 1.11 [95% CI, 1.01–1.22]) and as a trend treatment with alteplase (OR, 2.40 [95% CI, 0.93–6.96]). PH was associated with lower odds of favorable outcome (OR 0.25, 95% [CI 0.05–0.86]), while HI was not. Conclusion: Our results indicate that HI is associated with stroke severity, cardiovascular risk factors and thrombolysis. PH is a rare complication, more frequent in severe stroke and with thrombolysis. In contrast to HI, PH is associated with worse functional outcome. The impact of HT after MRI-guided intravenous alteplase for unknown onset stroke on clinical outcome is similar as in the trials of stroke thrombolysis within a known early time-window. Frontiers Media S.A. 2020-08-28 /pmc/articles/PMC7483750/ /pubmed/32982951 http://dx.doi.org/10.3389/fneur.2020.00957 Text en Copyright © 2020 Jensen, Schlemm, Cheng, Lettow, Quandt, Boutitie, Ebinger, Endres, Fiebach, Fiehler, Galinovic, Thijs, Lemmens, Muir, Nighoghossian, Pedraza, Simonsen, Gerloff and Thomalla. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Jensen, Märit
Schlemm, Eckhard
Cheng, Bastian
Lettow, Iris
Quandt, Fanny
Boutitie, Florent
Ebinger, Martin
Endres, Matthias
Fiebach, Jochen B.
Fiehler, Jens
Galinovic, Ivana
Thijs, Vincent
Lemmens, Robin
Muir, Keith W.
Nighoghossian, Norbert
Pedraza, Salvador
Simonsen, Claus Z.
Gerloff, Christian
Thomalla, Götz
Clinical Characteristics and Outcome of Patients With Hemorrhagic Transformation After Intravenous Thrombolysis in the WAKE-UP Trial
title Clinical Characteristics and Outcome of Patients With Hemorrhagic Transformation After Intravenous Thrombolysis in the WAKE-UP Trial
title_full Clinical Characteristics and Outcome of Patients With Hemorrhagic Transformation After Intravenous Thrombolysis in the WAKE-UP Trial
title_fullStr Clinical Characteristics and Outcome of Patients With Hemorrhagic Transformation After Intravenous Thrombolysis in the WAKE-UP Trial
title_full_unstemmed Clinical Characteristics and Outcome of Patients With Hemorrhagic Transformation After Intravenous Thrombolysis in the WAKE-UP Trial
title_short Clinical Characteristics and Outcome of Patients With Hemorrhagic Transformation After Intravenous Thrombolysis in the WAKE-UP Trial
title_sort clinical characteristics and outcome of patients with hemorrhagic transformation after intravenous thrombolysis in the wake-up trial
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7483750/
https://www.ncbi.nlm.nih.gov/pubmed/32982951
http://dx.doi.org/10.3389/fneur.2020.00957
work_keys_str_mv AT jensenmarit clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial
AT schlemmeckhard clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial
AT chengbastian clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial
AT lettowiris clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial
AT quandtfanny clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial
AT boutitieflorent clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial
AT ebingermartin clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial
AT endresmatthias clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial
AT fiebachjochenb clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial
AT fiehlerjens clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial
AT galinovicivana clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial
AT thijsvincent clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial
AT lemmensrobin clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial
AT muirkeithw clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial
AT nighoghossiannorbert clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial
AT pedrazasalvador clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial
AT simonsenclausz clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial
AT gerloffchristian clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial
AT thomallagotz clinicalcharacteristicsandoutcomeofpatientswithhemorrhagictransformationafterintravenousthrombolysisinthewakeuptrial